“As a reminder, these dynamics are more acute in the second half of the year, resulting in lower sales versus the first half.”

In context

“cross several newly-launched markets and remain focused on securing reimbursement. As we said previously, we are pursuing further development of Opdualag in a segment of first-line lung cancer and we remain on track to initiate our Phase 3 registrational program later this year. These expansion opportunities, coupled with the pending approval of nivolumab subcu further support extension of our I-O franchise into the next decade. In cardiovascular, on Slide 14, Eliquis remains the market leader anti-coagulant worldwide with global sales of more than $3 billion. In the US, sales were primarily driven by higher demand and market share gains. Sequentially, as is typical in the second quarter, US sales reflect an unfavorable gross-to-net impact as patients begin to enter Medicare Coverage Gap. As a reminder, these dynamics are more acute in the second half of the year, resulting in lower sales versus the first half. Turning to Camzyos, second quarter sales more than tripled compared to the prior year. Sequentially, US sales were driven mainly by demand. US demand in the second quarter was led by an increase of approximately 1,300 commercially dispensed patients since Q1, bringing the total to almost 6,900 patients on commercial drug. This growth demonstrates steady and consistent adoption. Outside the US, sales growth reflects the timing of reimbursement in approved markets and, globally, we see significant room for future growth. Let's turn to hematology on Slide 15. Sales of Reblozyl in the quarter grew 82% with growth in both US and international markets. In the US, sales benefited from higher demand, driven by first-line MDS associated anemia and some favorable inventory in gross-to-nets. Outside”